Skip to main content

Table 3 Additional HLA-B alleles that are significantly increased or decreased in the psoriatic arthritis cohort

From: Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype

HLA allele PsA (%), n= 359 PsA versus control PsO (%), n= 214 PsO versus control Control (%), n= 1,000 PsA versus PsO
B*27:05 15.6 2.6 (1.7 to 4.2) 4.7 P = 0.23 5.5 3.77 (1.9 to 7.6)
B*39:01 6.4 3.5 (1.6 to 7.6) 1.4 P = 1 1.2 2.86 (1.1 to 7.6)
B*08:01 37.3 1.6 (1.2 to 2.0) 24.8 0.43 (0.25 to 0.76) 30.1 1.81 (1.6 to 6.5)
B*44:02 14.8 0.53 (0.36 to 0.80) 22.4 P = 0.7 24.6 0.60 (0.29 to 0.87)
  1. Data presented as percentage or odds ratio (95% confidence interval). HLA, human leukocyte antigen; PsA, psoriatic arthritis; PsO, cutaneous psoriasis.